Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

88 The Efficacy and Safety of Amphetamine Extended-Release Oral Suspension (AMPH EROS) in Children with Attention-Deficit/Hyperactivity Disorder.

Kando JC, King T, Pardo A, Herman BK.

CNS Spectr. 2019 Feb;24(1):219-220. doi: 10.1017/S109285291900066X.

PMID:
30860001
2.

Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.

Childress AC, Kando JC, King TR, Pardo A, Herman BK.

J Child Adolesc Psychopharmacol. 2019 Feb;29(1):2-8. doi: 10.1089/cap.2018.0078. Epub 2018 Dec 21.

3.

Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.

Childress AC, Wigal SB, Brams MN, Turnbow JM, Pincus Y, Belden HW, Berry SA.

J Child Adolesc Psychopharmacol. 2018 Jun;28(5):306-313. doi: 10.1089/cap.2017.0095. Epub 2017 Dec 6.

4.

32 Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension (AMPH EROS) in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.

Childress AC, Pardo A, King TR, Kando JC, Herman BK.

CNS Spectr. 2019 Feb;24(1):191-192. doi: 10.1017/S1092852919000269.

PMID:
30859961
5.

87 Efficacy Measures in an Open-label Dose-Optimization of an Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.

Cutler A, Pardo A, King TR, Kando JC, Herman BK.

CNS Spectr. 2019 Feb;24(1):218-219. doi: 10.1017/S1092852919000658.

PMID:
30860000
6.

The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.

Childress AC, Brams M, Cutler AJ, Kollins SH, Northcutt J, Padilla A, Turnbow JM.

J Child Adolesc Psychopharmacol. 2015 Jun;25(5):402-14. doi: 10.1089/cap.2014.0176. Epub 2015 Feb 18.

7.

Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.

Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR.

J Child Adolesc Psychopharmacol. 2017 Feb;27(1):66-74. doi: 10.1089/cap.2016.0002. Epub 2016 May 16.

8.

A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.

Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R.

CNS Drugs. 2008;22(8):693-704.

PMID:
18601306
9.

NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.

Wigal SB, Childress AC, Belden HW, Berry SA.

J Child Adolesc Psychopharmacol. 2013 Feb;23(1):3-10. doi: 10.1089/cap.2012.0073. Epub 2013 Jan 5.

11.

Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.

Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D.

J Child Adolesc Psychopharmacol. 2017 Oct;27(8):690-699. doi: 10.1089/cap.2016.0177. Epub 2017 May 30.

12.

A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.

Wigal SB, Greenhill LL, Nordbrock E, Connor DF, Kollins SH, Adjei A, Childress A, Stehli A, Kupper RJ.

J Child Adolesc Psychopharmacol. 2014 Dec;24(10):562-9. doi: 10.1089/cap.2014.0100.

13.

Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day.

Wigal SB, Kollins SH, Childress AC, Adeyi B.

Child Adolesc Psychiatry Ment Health. 2010 Dec 14;4:32. doi: 10.1186/1753-2000-4-32.

14.

89 A Novel, Modified-Release Drug Delivery Technology Containing Amphetamine-Ion Exchange Complexes.

Herman BK, King TR, Kando JC, Pardo A.

CNS Spectr. 2019 Feb;24(1):220. doi: 10.1017/S1092852919000671.

PMID:
30860002
15.

Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.

Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R.

J Child Adolesc Psychopharmacol. 2008 Jun;18(3):248-56. doi: 10.1089/cap.2007.0015.

PMID:
18582179
18.

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.

Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y.

Biol Psychiatry. 2007 Nov 1;62(9):970-6. Epub 2007 Jul 12.

PMID:
17631866
19.

Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.

Lopez F, Silva R, Pestreich L, Muniz R.

Paediatr Drugs. 2003;5(8):545-55. Erratum in: Paediatr Drugs. 2003;5(12):832. Paediatr Drugs. 2003;5(10):661.

PMID:
12895137

Supplemental Content

Support Center